Testosterone deficiency in the adult males by Cachia, Mario J.
Throughout the ages, the search for eternal youth has led down 
many paths. The discovery of 
testosterone was, many believed 
the elixir which had, at long last, 
been found.  The medical use of 
testosterone, however, proved to be 
very challenging indeed and not quite 
the epitome of eternal youth as had 
been hoped for.1
Physiological functions of 
testosterone include protein 
synthesis with anabolic effects on 
muscle, erythropoiesis and bone.2 
It also favourably alters glucose 
and lipid metabolism.3 Testosterone 
promotes energy, drive, motivation, 
concentration and endurance.  It 
is also important in promoting 
psychosexual health and activity. All 
these are very important in promoting 
the well-being of the male individual.
Men are usually considered not 
to be subject to andropause4,5 but 
testosterone levels do decline with 
age (about 1.2% per annum from the 
age of 40, with about 12% of men 
above the age of 50 reaching 50% by 
80 years of age). The level at which 
testosterone deficiency in adults 
occurs is a hotly debated issue.  
There are several reasons for this:
1. different testosterone assays can 
give very variable testosterone 
levels; 
2. investigators use different assays 
in their studies whilst also taking 
different cut-off points; 
3. decreased libido and erectile 
dysfunction can occur at 
testosterone levels which vary 
from one individual to another. 
Matters are further complicated 
as testosterone levels, besides 
changing with age, are known to 
decrease with increasing body mass 
index; as well as increase for several 
hours after intercourse and also show 
diurnal variation. 
Given all the above problems, 
it is surprising that testosterone 
replacement therapy is ever 
initiated.6 Judicial use of testosterone 
replacement therapy will, however, 
improve the person’s well being, 
decrease the person’s cardiovascular 
risk parameters (although no large 
study has so far shown a decreased 
cardiovascular morbidity or mortality 
with therapy),7 improve muscle 
bulk, increase libido, correct erectile 
dysfunction (if there are no other 
causes e.g. long standing diabetes with 
neuropathy) and halt the decline of, or 
even improve, bone mineral density.
Conditions which are increasingly 
being identified as associated with low 
testosterone levels include diabetes8-11 
and the metabolic syndrome,8 
increasing age,5 heart failure,12 and 
obesity.13,14 
Given the variability of the assays 
and other variations as already 
mentioned above, the  indiscriminate 
clinical testing for testosterone 
deficiency is inappropriate.15 Targeting 
the correct, high risk individuals is the 
logical approach. Patients complaining 
of decreased libido and impotence 
should have a thorough history 
taking and examination looking for 
iatrogenic (e.g. beta-blocker therapy) 
or psychological causes prior to 
embarking on testosterone assay.  
High risk conditions include:
a. diabetes with another complaint 
e.g. impotence, decreased libido, 
decreased bone density, lethargy 
not explained by other causes;
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b. obese individuals with erectile 
dysfunction;
c. ‘non-intermittent’ impotence or lack 
of morning tumescence;  
d. osteoporosis. In a male this should 
always lead to an evaluation of 
testosterone levels as part of the 
investigations.
Most recent studies consider a total 
testosterone level of around 8 nmol/l as 
being the cut-off point for testosterone 
deficiency16,17 if certain criteria are met 
i.e. the sample is taken at around 10am 
and the individual has refrained from 
sexual activity for the past 24 hours. 
Once the diagnosis is made, then 
appropriate therapy has to be initiated.  
Testosterone replacement may not 
always be the appropriate therapy. 
For example, consider the case of 
a widowed 74 year old male with 
osteoporosis and prostate problems. 
The appropriate therapy here is 
treatment directed at the osteoporosis 
– testosterone therapy may exacerbate 
the prostate problem, and if he has no 
desire for sexual activity, may be totally 
inappropriate. 
For patients for whom testosterone 
therapy has been considered 
appropriate, then there are several 
options available, not all of which are 
available locally. Testosterone by oral 
route, although once popular has now 
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lost favour because of problems with 
hepatic first pass metabolism and 
erratic serum levels.  Testosterone 
gels and patches utilise the cutaneous 
route of administration and are fairly 
popular, but require at least a daily 
application.  The main problem is 
transfer of testosterone to a female 
partner (possibly also to minors in the 
family) if the proper precautions are 
not taken.  Parenteral testosterone 
esters are perhaps the most popular, 
although not always legitimately 
used e,g, in body building and other 
performance sports.  Most companies 
are now discontinuing most of these 
esters, causing supply and therapy 
problems. This has mainly arisen as 
a consequence to the ‘hacking’ of 
the Chinese undecanoate ester to the 
European market. This product only 
requires an injection at approximately 
three monthly intervals. Its rise in 
popularity has resulted in companies 
discontinuing production of other 
esters. Various other modes of 
administration are at present under 
review, such as implants. 
Side effects are relatively few and 
mild if used appropriately. The most 
common is polycythaema, which 
often requires a decrease in dose and 
sometimes necessitates discontinuation 
of therapy. Liver dysfunction is probably 
the second most common side-effect.  
Uncontrollable rage and aggression has 
been reported, but is usually related to 
supra-pharmacological doses in abuse.   
Prostate problems, although often cited, 
are probably not an issue. No study has 
really shown an increase in prostate 
problems, including prostate cancer.  In 
addition some studies have shown that 
the testosterone receptors on the prostate 
are easily saturated, so testosterone 
therapy does not really increase prostatic 
stimulation.18 
Testosterone replacement can be a 
rewarding therapy, however, the pitfalls in 
diagnosis are such that specialist advice 
should be sought prior to initiation of any 
such therapy.  
Testosterone deficiency leads to multiple 
problems but can be difficult to diagnose. 
However, replacement therapy can be 
rewarding and a life changer for the patient
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